Anand Srivastava

Dr. Anand Srivastava has been associated with leading universities and research institutions in the United States. In affiliation with the University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, and University of California Los Angeles Medical College (UCLA) Dr. Srivastava has developed several research projects and has extensive experience in the clinical and research field of Stem Cells, which is well documented in many scientific journals.

Dr. Anand Srivastava has rooted his unique background of expertise in Stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research. As a scientist working in a narrowly defined field, Dr. Srivastava has a broad and multidisciplinary approach in these clinical research fields to align directly with the mission of GIOSTAR and ongoing projects in the disciplines.

Dr. Anand Srivastava’s research work has been presented in various international scientific conferences in India, Japan, Germany, and the United States. His abstracts have been published in peer reviewed medical scientific journals and cited extensively by other scientists. Dr. Anand Srivastava’s scientific achievements were recognized by many scientific fellowships and he was consecutively awarded the highly prestigious and internationally recognized, JISTEC award from the Science and Technology Agency in Japan. Dr. Srivastava’s research presentation was awarded at the Meeting of Clinical Chemistry and Medicine, Kyoto, Japan.

Dr Anand Srivastava demonstrates expertise in genetic engineering research, developmental biology, immunology, and animal transgenics. He has leant his expertise in the field of searching and characterizing new genes for ongoing developments in the treatments for the many degenerative diseases, congenital diseases, and cancer. His biography has been included in “Who is Who in America”, in 2005, 2010, and he has achieved the United States Congressional Recognition for his contributions in the field of Stem Cell Science.

Dr. Srivastava is a Chairman and Cofounder of Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California. The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases such as Parkinson’s, Alzheimer’s, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. GIOSTAR is a leader in developing highly advanced stem cell-based technology, supported by leading scientists with pioneering publications in stem cell biology. GIOSTAR’s primary focus is to discover and develop a cure for human diseases implementing stem cell-based therapies and products. The development of Regenerative Medicine provides promise for treatments of diseases previously regarded as incurable.

GIOSTAR is the world’s leading Stem cell research company involved with stem cell research work for over a decade. Several governments within the United States, India, China, Turkey, Kuwait, Thailand, Philippines, Bahamas, Saudi Arabia seek Dr. Srivastava’s guidance on drafting their national policy formulations and program directions in the area of stem cell research, development, and regulations. Under his leadership, a group of esteemed scientists and clinicians have developed and established Stem cell therapy for various types of autoimmune diseases and blood disorders, which are being offered to patients in the United States and soon offered on a regular clinical basis to the people around the globe. GIOSTAR implemented a stem cell treatment center at Surat Civil Hospital for the less fortunate tribal populations suffering from Sickle Cell in the southern belt of Gujarat, India. Several states of government within India rely on the collaborative efforts of GIOSTAR and Dr. Anand to continue implementing stem cell transplant programs.